HomeStocks
RMD
Director Trades
| Date | Director | Value |
|---|
Company News
Apr 24, 2025 • 10:39 PM
ASX 200BiotechnologyResMed delivers double-digit EPS growth on increasing demand for sleep apnoea devices
ResMed (ASX: RMD) has reported double-digit earnings per share (EPS) growth for the three months to March on the back of increasing market demand for its best-in-class sleep apnoea products and software solutions. The company’s revenue for the period increased by 8% to US$1.3 billion (up 9% on a constant currency basis), while income from […]
Jun 26, 2024 • 7:27 PM
ASX 200TechnologyResMed shares hit as Eli Lilly’s weight loss drug demonstrates sleep apnoea benefits
Medical device maker ResMed (ASX: RMD) saw its shares tumble more than 13% after pharmaceutical rival Eli Lilly announced that its weight-loss drug Zepbound (tirzepatide) could also help resolve sleep apnoea in some patients. California-based ResMed is a giant in the sleep apnoea space, manufacturing face masks, nasal devices and continuous positive airway pressure (PAP) […]